Eli Lilly stock surges 11% on obesity pill’s success in first late-stage trial
Eli Lilly’s experimental obesity pill, orforglipron, met its main goals in a closely watched late-stage trial, boosting the company’s standing...
Eli Lilly’s experimental obesity pill, orforglipron, met its main goals in a closely watched late-stage trial, boosting the company’s standing...
The S&P 500 and Nasdaq Composite opened higher on Thursday, the final trading day of the week.The Dow Jones Industrial...
Hertz Global Holdings Inc (NASDAQ: HTZ) is up nearly 50% in premarket on Thursday after billionaire investor Bill Ackman announced...
The Nikkei 225 index has bounced back this month as the US and Japan continued their negotiations on tariffs. After...
The FTSE 100 and FTSE 250 indices have rebounded over the past two weeks as European stocks have emerged as...
GE Aerospace’s stock price is under pressure in 2025 as last year’s rally takes a breather and as investors assess...
The ServiceNow stock price has declined significantly over the past few months, dropping from a high of $1,196 in January...
The S&P 500 index has declined significantly over the past few months, forming a death cross pattern for the first...
OpenAI is in talks to pay about $3 billion to acquire Windsurf, an artificial intelligence tool for coding help, CNBC...
Lyft is positioning itself for a larger role in the global rideshare market, even as analysts remain divided on its...
Disclaimer: EarningsMastery.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.